Skip to main content
letter
. 2015 Aug;100(8):e315–e317. doi: 10.3324/haematol.2015.124297

Figure 2.

Figure 2.

Proteasome inhibitors abrogate lenalidomide induced IKZF1 degradation in a dose- and time-dependent fashion. (A and B) Bortezomib and carfilzomib abolished lenalidomide–induced degradation of IKZF1. 8226/IKZF1Luc cells were treated with lenalidomide for 24 h alone or with the indicated doses of bortezomib (A) or carfilzomib (B), and luciferase activities as a measure of IKZF1 degradation were measured. (C) Blockage of lenalidomide induced IKZF1 activity by BOR is dose- and time-dependent. 8226/IKZF1Luc cells were pre-treated with the indicated doses of bortezomib for different times, then BOR was washed off. LEN (2 μM) was added and incubated for 24 h. (D) 8226 cell viability measured by MTT (normalized to DMSO), cells were treated with BOR for 72 h.